1. HOME
  2. IR Information
  3. Qol HD At-A-Glance
  4. "Stable management" underpinned by two businesses

"Stable management" underpinned by two businesses

Our core Pharmacy Business, and our Medical-Related Business which does not rely on the general healthcare system

The Qol Group is currently demonstrating stable management, thanks to optimization of the business portfolio, with the core Pharmacy Business and the Medical-Related Business, which does not rely on the general healthcare system, as the two pillars of earnings.

Pharmacy Business: Sales grows and stable revenue. Medical-Related Business: high revenue.

Pharmacy Business

With "Always there to care" as our slogan, we are rolling out "Qol Pharmacies" in a range of formats based on convenience for users, including one-on-one pharmacies with medical institutions.

The Pharmacy Business is comprised of four companies: Qol, Ryukyu Qol, KYOEIDO, and Pharmaster. Within these four companies, Qol Pharmacies are community-based pharmacies as well as Qol Pharmacies "Machinaka (in-town)" Pharmacies: LAWSON, LIFE, MUJI CO., LTD., "Ekichika (close-to-station)" Pharmacies: Bic Camera, "Ekinaka (in-station)" Pharmacies: Tokyu Co., Ltd. Through collaboration with other industries, which are the industry's first initiative, we are opening stores in various forms, including "Machinaka (in-town)" "Ekichika (close-to-station)" "Ekinaka (in-station)".

Point1Our core "one-on-one pharmacy", model for store expansion

We achieve efficient store management through close collaboration with the medical institutions that issue prescriptions

Point2Machinaka, Ekichika and Ekinaka healthcare pharmacies

We collaborate with companies in different industries such as Lawson and BIC Camera to open even more convenient pharmacies in excellent locations

Medial-Related Business

The Medica-Related Business consists of the pharmaceutical manufacturing business, the CSO business (dispatch of MRs), the CRO business (clinical trial support services), the medical staffing agency business, and the medical publishing business.

The Medical-Related Business is comprised of DAIICHI SANKYO ESPHA and Fujinaga Pharm (Pharmaceutical Manufacturing Business), APO PLUS STATION (CSO and CRO Business), APO PLUS CAREER (Medical Professional Referral Dispatch Business), and Medical Qol (Publishing-related Business).

  • *CSO: Contact Sales Organization
  • *CRO: Contract Research Organization

Pharmaceutical manufacturing business

Point1Delivery of high quality, affordable drugs through promotion of the widespread use of authorized generic drugs (AGs) (DAIICHI SANKYO ESPHA)

Authorized generics are generic drugs with the same active and inactive ingredients and manufacturing methods as original drugs (brand-name drugs), manufactured with the brand company's permission and generic drugs that may be marketed by the brand company's licensee with the brand company's permission.
We make high-quality drugs available to patients at more affordable prices than the original drugs.

Details are available here.

Point2High-quality, safe products that meet patient needs

We leverage synergies with our Pharmacy Business to provide a stable supply of high quality-safe products that meet patient needs.

Net sales and operating profit composition ratios by business (FY03/2024)

Consolidated net sales were ¥180 billion. Of this, \165 billion was in the Pharmacy Business, accounting for 92%. The Medical-Related Business was \14.9 billion, accounting for the remaining 8%. Within the Pharmacy Business, dispensing fees are ¥153.4 billion and others are ¥11.6 billion. Operating profit is \11.8 billion. Of this, \10.7 billion was in the Pharmacy Business, accounting for 91%. The Medical-Related Business was \1.1 billion, accounting for the remaining 9%. This does not include elimination or corporate.

Point3Major change in business structure with acquisition of DAIICHI SANKYO ESPHA (April 2024)

DAIICHI SANKYO ESPHA CO., LTD. (Pharmaceutical Manufacturing Business) became a consolidated subsidiary in April 2024.
Net sales and operating profit composition ratios by business are expected to be as follows going forward.

In the fiscal year ended March 31, 2023, pharmacy business accounted for the majority of net sales, but in the future business composition, the image is that pharmacy business and medical-related business will be halved each other. In the fiscal year ended March 31, 2023, insurance pharmacy business accounted for the majority of operating profit, but in the future business structure, medical-related business account for more than half of total operating profit.